Related Experiment Video
Updated: Jan 31, 2026

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
Published on: March 25, 2016
The role of febuxostat in gout
Thomas Bardin1,2,3, Pascal Richette1,2,3
1Department of Rheumatology, Hôpital Lariboisière, APHP.
Insights
Febuxostat use in gout patients with cardiovascular disease showed a higher risk of cardiovascular death compared to allopurinol. Guidelines for gout management should be revised, prioritizing allopurinol or uricosurics over febuxostat in certain patients.
Area of Science:
- Cardiology
- Rheumatology
- Pharmacology
Background:
- Cardiovascular safety concerns surround febuxostat, a urate-lowering drug used in gout management.
- Gout management requires careful consideration of drug safety, especially in patients with pre-existing cardiovascular conditions.
Purpose of the Study:
- To evaluate the cardiovascular safety of febuxostat compared to allopurinol in patients with gout and major cardiovascular disease.
- To inform revised clinical guidelines for gout management based on new safety data.
Main Methods:
- The Cardiovascular Safety of Febuxostat and Allopurinol in Gout (CARES) trial was a randomized controlled trial.
- Approximately 6190 patients with gout and cardiovascular disease were randomized to febuxostat or allopurinol.
- Patients were followed for a median of 32 months to assess cardiovascular outcomes.
Main Results:
- No significant difference was observed in the composite primary endpoint between febuxostat and allopurinol.
- However, cardiovascular death was significantly more frequent in the febuxostat group (4.3%) compared to the allopurinol group (3.2%) (P=0.03).
Conclusions:
- Current guidelines for gout management require revision due to the increased cardiovascular death risk associated with febuxostat.
- Allopurinol is recommended as the first-line urate-lowering drug for gout patients without contraindications.
- In patients with cardiovascular disease/risk factors and no history of uric acid stones, uricosurics may be preferred over febuxostat if allopurinol is contraindicated.
Purpose Of Review:
Concerns about the cardiovascular safety of febuxostat lead to reconsideration of the place of febuxostat in the management of gout.
Recent Findings:
The CARES trial is a randomized controlled trial mandated by the FDA to compare the cardiovascular safety of febuxostat and allopurinol in the management of gout. About 6190 patients with gout and major cardiovascular disease, randomly assigned to allopurinol or febuxostat, were prospectively followed up for a median of 32 months. No difference was noted in the occurrence of the primary end-point event, a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or unstable angina with urgent revascularization, but cardiovascular death was significantly more common in the febuxostat group (4.3%) as compared with the allopurinol group (3.2%) (P = 0.03).
Summary:
Present guidelines on the management of gout should be revised in view of recent findings. Allopurinol could be recommended as the sole first-line urate-lowering drug (ULD) in patients with no contraindication. In patients contraindicated to allopurinol, uricosurics could be preferred to febuxostat as first-line ULDs in patients with cardiovascular disease/risk factors and no history of uric acid stones.
More Related Videos
Related Concept Videos
Role of Septins
Cellular Functions of Septins
Recent studies have revealed the multifaceted roles of septins in various cellular processes such as cytokinesis, ciliogenesis, and neurogenesis. Septins act as scaffolds and...
The Role of Culture
Role-Based Identity
Role of Hippocampus in Memory
Role of ER in the Secretory Pathway
Components of the secretory pathway
About a third of proteins synthesized in the cell are sorted via the secretory route. They shuffle between different compartments in membrane-bound vesicles until they reach their final destination. The main intracellular compartments involved...
Role of Amygdala in Memory
One of the...

